DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

ISRG·Intuitive Surgical, Inc.

$.
-. (-.%)
After Hours
High
$415.00
Open
$412.90
Market Cap
145.47B
52W High
$603.88
Low
$403.25
P. Close
$406.73
P/E
48.83
52W Low
$396.68
Fwd P/E
162.56
DailyIQ Est.
$592.19
Technical Score (1D)
23
SELL
News Sentiment
49
MIXED
The most immediate event is Intuitive Surgical’s voluntary recall of certain Da Vinci system components due to a potential E‑brake pin defect, announced just 3.7 hours ago. The recall has already weighed on short‑term share momentum, highlighting heightened regulatory and operational risk that could damp near‑term earnings. The company must address the recall swiftly to mitigate reputational damage and maintain market confidence, as any delay could prolong the negative sentiment. Meanwhile, analysts are eyeing the upcoming Q2 fiscal 2026 earnings release on July 16, which is expected to report EPS of $2.48 and revenue of $2.81 billion, both up 13–15% YoY. Evercore has trimmed its target price to $430 from $480 but kept an In‑Line rating, reflecting confidence in stable demand and healthy procedure volumes despite the recall. The firm also projects da Vinci procedure growth of 13.5%–15.5% internationally, driven by continued spending on new equipment across the industry. Non‑GAAP gross margin is forecast between 67.5% and 68.5%, with other income of $315–$335 million largely due to share repurchases, which could offset some recall‑related costs. Traders should watch how quickly Intuitive resolves the recall, any adjustments to the Q2 guidance, and whether the earnings release confirms the projected growth trajectory. The recall’s resolution and the earnings outcome will be the key catalysts for the next 1–10 trading days, as they will determine whether the market views the incident as a one‑off risk or a sign of deeper operational issues.
Earnings Summary
Intuitive Surgical (ISRG) is a medical technology company that develops and sells the da Vinci Surgical System and the Ion endoluminal system, positioning itself as a leader in minimally invasive robotic surgery and diagnostic procedures. The company operates in the healthcare sector, specifically within medical instruments and supplies, and relies on a global direct‑sales model to deliver its products and support services to hospitals worldwide. In the most recent two quarters, ISRG reported Q4 2025 revenue of $2.866 billion and EPS of $2.53, up from Q1 2026 revenue of $2.770 billion and EPS of $2.50. Compared to the preceding two quarters—Q2 2025 revenue $2.440 billion, EPS $2.19 and Q3 2025 revenue $2.505 billion, EPS $2.40—both revenue and EPS have accelerated, with year‑over‑year revenue growth of roughly 19 % and EPS growth of about 14 %. The company has consistently beat analyst estimates, posting earnings per share above forecasts in six of the last seven quarters, and has maintained a strong revenue trajectory. Over the past several years, ISRG’s YoY revenue growth has trended upward, moving from $2.413 billion in Q4 2024 to $2.866 billion in Q4 2025, while EPS has risen from $2.21 to $2.53, reflecting disciplined cost management and expanding procedure volumes. The company’s earnings history shows a pattern of robust revenue growth coupled with margin expansion, even as it navigates competitive pressures and regulatory scrutiny. Recent market commentary highlights a 68 % probability that ISRG will finish between $280 and $610 over the next year, driven by strong Q4 execution and a 17 % jump in procedure volume, while noting persistent headwinds. BMO Capital’s Outperform rating and $518 price target underscore confidence in continued revenue expansion and margin improvement, though Evercore’s price target cut to $430 signals caution amid reimbursement constraints for appendectomy procedures. Investors should watch for the next earnings release to confirm guidance on procedure volume growth, margin trends, and any updates on regulatory approvals or reimbursement policy changes, as these factors will shape the company’s valuation and market perception in the coming quarter.

EPS

EstBeatMiss
$1.61$1.87$2.13$2.39$2.65Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.50 - -
Q1'26$2.11$2.50+18.7%
Q4'25$2.30$2.53+9.8%
Q3'25$1.99$2.40+20.7%
Q2'25$1.92$2.19+14.1%
Q1'25$1.73$1.81+4.4%

Revenue

EstBeatMiss
$2.2B$2.4B$2.6B$2.8B$3.0BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$2.9B - -
Q1'26$2.6B$2.8B+5.8%
Q4'25$2.8B$2.9B+2.4%
Q3'25 - $2.5B -
Q2'25 - $2.4B -
Q1'25 - $2.3B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

ISRG Stock Snapshot

ISRG is currently trading at $407.01, giving Intuitive Surgical, Inc. a market cap of 145.47B and a P/E ratio of 48.8. Today's range spans $403.25–$415.00, with shares opening at $412.90 and moving up $0.28 (0.1%) from the prior close. DailyIQ's technical score sits at 23/100 (SELL) with a news sentiment reading of 49/100.

Over the past year ISRG has traded between $396.68 and $603.88 - the current price is +2.6% off the 52-week low and -32.6% from the high. 41 analysts cover the stock with a Buy consensus and a mean 12-month target of $561.84 (range $366.00–$750.00), implying upside of +38.0%.

The options market is expressing concern about ISRG - elevated put activity in large-cap Healthcare names with SELL signals (23/100) is common when the technical and sentiment inputs (neutral, 49/100) both deteriorate. Price: $407.01 (near 52-week lows). (P/E: 48.8) At 145.47B in capitalization, that hedging activity from institutional holders can become a feedback loop that amplifies the initial selling pressure. Range: $396.68–$603.88.

Analyst coverage for ISRG becomes a double-edged factor in a SELL phase: at 145.47B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 23/100 technical reading and neutral sentiment (49/100) at $407.01 (near 52-week lows) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $396.68–$603.88 range establishes where that repricing lands.